Platinum–DNA adduct

Platinum–DNA adducts are covalent complexes formed when platinum-based chemotherapy drugs, such as cisplatin, bind to the N7 position of purine bases (primarily guanine) in DNA[2][3]. This results in multiple lesion types, including 1,2-intrastrand crosslinks (GpG, ApG), 1,3-intrastrand crosslinks, interstrand crosslinks, and monofunctional adducts[3]. The formation of these adducts disrupts DNA replication and transcription, activates cellular DNA damage responses, and ultimately leads to apoptosis. Platinum–DNA adduct formation is the primary cytotoxic mechanism of platinum drugs, and levels of adducts are associated with efficacy and toxicity in cancer therapy[3]. The “target” in this context is the cellular DNA itself, not a receptor or enzyme, but the biological effect results from platinum-induced modification of DNA structure and function, impairing cellular proliferation and survival[2][3].

Other names

Platinum–DNA adductPt–DNA adductDNA–platinum complexPlatinum cross-link (context-dependent)Cisplatin–DNA adduct

Covalent binding of platinum to DNA bases (mainly guanine), forming intrastrand and interstrand crosslinks, as well as monofunctional adducts, leading to DNA polymerase stalling, inhibition of transcription and replication, activation of DNA damage response, and cell death[2][3].